Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP2138 in CLDN18.2-positive gastric/GEJ and pancreatic adenocarcinoma
jRCT2031210644Phase 1Recruiting
- Sponsor
- Astellas Pharma
- Start
- Jun 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of ASP2138 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and pancreatic adenocarcinoma (PDAC) (5 arms), sponsored by Astellas Pharma. Primary endpoints: Dose-limiting toxicities, Adverse events / serious adverse events and 5 more. Started Jun 2022; status: recruiting.
02
Drugs
ASP2138
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomapancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2031210644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210644.